- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Du Pont, ImaRx sue MBI, Mallinckrodt
Du Pont Pharmaceuticals and ImaRx Pharmaceutical this month began another chapter in the patent infringement saga in which the companies have been embroiled since 1997. The two firms filed suit in a U.S. District Court in Delaware against Molecular
Du Pont Pharmaceuticals and ImaRx Pharmaceutical this month began another chapter in the patent infringement saga in which the companies have been embroiled since 1997. The two firms filed suit in a U.S. District Court in Delaware against Molecular Biosystems and Mallinckrodt, claiming infringement on patent no. 5,547,656. ImaRx owns the patent and licenses it to Du Pont.
The patent in question covers low-density, perfluorocarbon gas-filled microspheres used in ultrasound contrast agents, including Du Ponts Definity product. Du Pont submitted a new drug application to the Food and Drug Administration for Definity last December and is awaiting clearance (SCAN 12/16/98).
The suit came less than a week after the U.S. Patent and Trademark Office upheld the patent, bolstering North Billerica, MA-based Du Pont and Tucson-based ImaRxs confidence in their intellectual property position. On April 29, the PTO affirmed all 62 of the patents claims without amendment.
The PTOs decision resolves one of two patent challenges brought against Du Pont and ImaRx in 1997 by MBI of San Diego and Mallinckrodt of St. Louis. Du Pont expects to receive a decision from the PTO in the near future regarding the other patent under reexamination, according to the company.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
